Pantoprazole Accord Healthcare

Pantoprazole, the active ingredient in Pantoprazole Accord Healthcare, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and ulcers in adult patients. GNH USA supplies Pantoprazole Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Pantoprazole Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders: - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the esophageal lining. - Erosive oesophagitis: heals erosive lesions in the esophagus. - Peptic ulcer disease (duodenal and gastric ulcers): supports ulcer healing and reduces recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with this rare condition. - Maintenance therapy after ulcer healing: helps prevent recurrence of ulcer symptoms.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually transient. - Nausea: occasional and mild. - Abdominal pain: mild discomfort. - Flatulence: excess gas. - Constipation: infrequent.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): requires immediate medical attention. - Clostridioides difficile infection: may present with persistent diarrhea. - Low magnesium levels (hypomagnesemia): can cause muscle cramps or cardiac arrhythmia. - Bone fractures: associated with long‑term use. - Acute interstitial nephritis: renal inflammation requiring evaluation.

When prescribing Pantoprazole, clinicians should consider several safety aspects: - Renal impairment: adjust monitoring for patients with reduced kidney function. - Hepatic impairment: use with caution in moderate to severe liver disease. - Long‑term therapy: evaluate need for periodic reassessment to avoid unnecessary prolonged use. - Pregnancy and lactation: weigh potential benefits against risks; use only if clearly indicated. - Drug interactions: review concomitant medications for possible PK/PD interactions. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Pantoprazole may affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Ketoconazole oral suspension: reduced absorption leading to loss of antifungal efficacy. - Atazanavir: markedly decreased plasma concentrations, compromising HIV treatment.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring more frequent coagulation monitoring. - Methotrexate: may increase serum levels, especially at high doses. - Digoxin: slight increase in serum concentration; monitor for toxicity. - Clopidogrel: potential reduction in antiplatelet effect; consider alternative therapy.